Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cholera Vaccine
V. cholerae polysaccharide fragments are immunogenic in mice
September 5th, 2004
Synthetic fragments of Vibrio cholerae O1 inaba O-specific polysaccharide bound to a protein carrier are immunogenic in mice but do not induce protective antibodies. According to a study from the United States, "Development of Vibrio cholerae lipopolysaccharide (LPS) as a cholera vaccine immunogen is justified by the correlation of vibriocidal anti-LPS response with immunity. Two V. cholerae 01 LPS serotypes, Inaba and Ogawa, are associated with endemic and pandemic cholera. Both serotypes induce protective antibody following infection or vaccination. Structurally, the LPSs that define the serotypes are identical except for the terminal perosamine...
Source: Medical Letter on the CDC & FDA (2004-09-05)
|
